Johnson & Johnson Option Alert: Jun 20 $145 Puts at the Bid: 8858 vs 3557 OI

Johnson & Johnson Option Alert: Jun 20 $145 Puts at the Bid: 8858 @ $2.04 vs 3557 OI; Ref=$153.86

Johnson & Johnson (NYSE:JNJ) Bolsa

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Johnson &amp; Johnson reportará ganancias del cuarto trimestre. Analiza sus ingresos, expansión de Spravato y opiniones de analistas clave.

Johnson &amp; Johnson (JNJ) reportará ganancias del 4T: ¿Qué opinan los analistas?

IBKR

NFLX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: ABT, NFLX, PG, IBKR y JNJ.

5 acciones en el foco este miércoles: ABT, NFLX, PG, IBKR y JNJ

Dividends

AMGN

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

Descubre las acciones del Dow Jones con los rendimientos por dividendos más altos para 2025. Conoce estrategias populares.

Acciones con mayores dividendos del Dow Jones: Las mejores opciones para 2025

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) on Thursday unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">over the next five years</a>.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
As part of the initiative, Novartis will build seven new facilities — four focused on manufacturing and two dedicated to radioligand therapy (RLT) — and expand three existing RLT production sites.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/04/44751289/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
These efforts are expected to generate nearly 1,000 new jobs at Novartis and support around 4,000 additional roles.
The move comes after U.S. President Donald Trump on Tuesday disclosed plans for a &#8220;major tariff&#8221; on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
On Wednesday, President Donald Trump announced a 90-day pause on tariffs for countries that have not retaliated against U.S. trade measures.
&#8220;As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the U.S. that supports our ability to find the next medical breakthroughs for patients,&#8221; <a href="https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years" target="_blank" rel="noreferrer noopener">said</a> Vas Narasimhan, CEO of Novartis. &#8220;We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook, and 2027 core margin guidance of 40%+.&#8221;
The investment includes a newly planned&nbsp;$1.1 billion&nbsp;research hub in&nbsp;San Diego, a research facility for scientific infrastructure and drug discovery.
The new complex, expected to open between 2028 and 2029, will serve as the epicenter of the Novartis West Coast Biomedical Research presence, complementing existing hubs in Cambridge, Massachusetts, and Basel, Switzerland.
In addition, the company will be expanding RLT manufacturing with new facilities in&nbsp;Florida&nbsp;and&nbsp;Texas.
To support growing demand for RLTs in the U.S., Novartis has expanded production capabilities in Millburn, New Jersey, and a state-of-the-art facility in Indianapolis, Indiana, and is building a third US RLT manufacturing facility in Carlsbad, California.
The total investment in Novartis&#8217; U.S. operations is expected to be nearly $50 billion over the next five years.
Earlier this year, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>, while Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced to double its U.S. drug manufacturing spending from $23 billion to <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">$50 billion within five years</a>.
A Wedbush analyst said on Tuesday that building a factory in the U.S. <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">takes four to five years</a>. The analyst explains that high labor costs and other expenses in the U.S. don't align with how modern supply chains are designed to operate.
NVS Price Action: Novartis stock is up 2.33% at $103.40 during the premarket session at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44752669/walmarts-resilience-shines-with-broad-ebit-forecast-and-strong-growth-engines-analyst-says" target="_blank" rel="noreferrer noopener">Walmart&#8217;s Resilience Shines With Broad EBIT Forecast And Strong Growth Engines, Analyst Says</a></li>
</ul>
Photo: Highly trained specialists on the production line of Novartis&#8217; radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, courtesy Novartis.

Biotech

Large Cap

Health Care

General

Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs.
What Happened: The rally in pharma stocks was short-lived after the stocks reversed course on Thursday. When a reporter asked President Trump if he would go ahead and levy tariff duties on pharmaceutical stocks, he said, &#8220;Yeah, well, I will be because we want them coming back.&#8221;
&#8220;You know, we realized during COVID-19 that we don&#8217;t make our drugs and our pharmaceuticals in this country. So, I realized that, and it was a big realization,&#8221; he added.
Citing the emergency during COVID-19, he stated that he wanted the pharma companies to produce drugs in the U.S.
&#8220;We had to go to China to get drugs, we had to go to other places, we don&#8217;t make it. That&#8217;s because we let them leave, and now if they want to come back, we&#8217;re going to put tariffs on the pharmaceutical companies, and they&#8217;re going to all want to come back,&#8221; Trump said.
The pharma stocks tumbled on Thursday after Trump&#8217;s confirmation of tariffs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>Thursday&#8217;s Performance</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44755181/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Why It Matters: Despite a 90-day pause on reciprocal tariffs, base global tariffs of 10% and China tariffs of 125%, along with sector-specific tariffs of 25% on steel and aluminum, auto, and auto parts remain in place. Adding to it, the President hinted that he could soon announce tariffs on pharmaceutical companies.
Here are some of the pharmaceutical industry-linked exchange-traded funds that could be impacted.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: After Thursday&#8217;s fall, following Wednesday&#8217;s rebound, the Nasdaq 100 index was 17.46% lower than its previous high of 22,222.61 points. The S&amp;P 500 index was down 14.31% from its record of 6,147.43 points, and the Dow Jones declined 12.16% from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended lower on Thursday. The SPY was down 4.38% to $524.58, while the QQQ declined 4.25% to $446.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cortez-demands-disclosure-from-congress-members" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies

Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) on Thursday announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">adolescents and adults simultaneously</a>.
The ICONIC program, with icotrokinra (JNJ-2113) data from a subgroup analysis, came about through a partnership with Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
Data at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting show adolescents treated with once daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo, with no new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44732319/icotrokinra-results-show-75-of-adolescents-with-plaque-psoriasis-achieved-completely-clear-skin-a" rel="noreferrer noopener">safety signals identified</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44220449/why-is-protagonist-therapeutics-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Protagonist Therapeutics Stock Trading Higher On Monday</a>?
Key findings from the adolescent cohort of the ICONIC-LEAD study:
<ul>
<li>At week 16, 84.1% of adolescent patients treated with once daily icotrokinra achieved an Investigator&#8217;s Global Assessment (IGA) score of 0/1 (clear or almost clear skin)</li>
<li>70.5% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and 13.6% receiving placebo, respectively.</li>
<li>Response rates continued to improve through Week 24, where 86.4% of adolescents achieved IGA 0/1 and 88.6% achieved PASI 90.</li>
<li>At week 24, 75% of adolescents achieved IGA 0 (completely clear skin), and 63.6% achieved PASI 100.</li>
<li>Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks. No new safety signals were identified.</li>
</ul>
In March, Protagonist Therapeutics announced new icotrokinra (JNJ-2113) data from the comprehensive Phase 3 clinical program and the planned initiation of the first-ever head-to-head <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44209279/icotrokinra-clinical-study-results-demonstrate-its-potential-to-shift-treatment-paradigm-and-set-" rel="noreferrer noopener">study in plaque psoriasis</a>.
Nearly half of the patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin at Week 24.
Price Action: PTGX stock is down 0.16% at $42.50, and JNJ stock is down 0.11% at $150.81 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44721901/post-holdings-to-shut-two-cereal-plants-amid-falling-demand-cuts-300-jobs" target="_blank" rel="noreferrer noopener">Raisin Bran Maker Post Holdings To Shut 2 Cereal Plants As Demand Falls, Cuts 300 Jobs</a></li>
</ul>
Image: Shutterstock

PTGX

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) price target from $30 to $39. Wells Fargo analyst Jeff Cantwell upgraded the rating from Underweight to Overweight. Toast shares closed at $34.38 on Wednesday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim slashed the price target for Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) from $15 to $13. Guggenheim analyst Subbu Nambi maintained a Buy rating. Neogen shares closed at $5.02 on Wednesday. <a href="https://www.benzinga.com/quote/NEOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS lowered BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) price target from $38 to $31. UBS analyst Joseph Spak downgraded the stock from Buy to Neutral. BorgWarner shares closed at $26.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities cut the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $263 to $216. Truist Securities analyst Jailendra Singh maintained a Buy rating. IQVIA shares closed at $157.02 on Wednesday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $171 to $159. B of A Securities analyst Tim Anderson maintained a Neutral rating. Johnson &amp; Johnson shares closed at $150.97 on Wednesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital slashed Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) price target from $275 to $170. Loop Capital analyst Mark Schappel downgraded the stock from Buy to Hold. Manhattan Associates shares settled at $166.26 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Barclays cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $55 to $50. Barclays analyst Manav Patnaik upgraded the stock from Underweight to Equal-Weight. ManpowerGroup shares closed at $52.87 on Wednesday. <a href="https://www.benzinga.com/quote/MAN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $265 to $230. Truist Securities analyst Youssef Squali maintained a Buy rating. Amazon shares closed at $191.10 on Wednesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $4.2 to $3.5. Mizuho analyst Vijay Rakesh maintained a Neutral rating. NIO shares settled at $3.31 on Wednesday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $208 to $185. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Alphabet shares closed at $158.71 on Wednesday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png" alt="" class="wp-image-865996" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

GOOGL

MANH

NEOG

TOST

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and lowers the price target from $171 to $159.

B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $159

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously
84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
SPRING HOUSE, Pa., April 10, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis (PsO) to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously. These data, presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting, show adolescents treated with once daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo with no new safety signals identified.1 Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor and is being studied in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO.
In the study, 84.1% of adolescent patients treated with once daily icotrokinra achieved an Investigator&#39;s Global Assessment (IGA)b score of 0/1 (clear or almost clear skin) and 70.5% achieved a Psoriasis Area and Severity Index (PASI)c 90 response, compared to 27.3% and 13.6% receiving placebo, respectively, at Week 16.1&nbsp;
Response rates continued to improve through Week 24 where 86.4% of adolescents achieved IGA 0/1 (clear or almost clear skin) and 88.6% achieved PASI 90.1 Further, at Week 24, 75% of adolescents achieved IGA 0 (completely clear skin) and 63.6% achieved PASI 100.1

Johnson & Johnson Presents Icotrokinra Results Showing 75% Of Adolescents With Plaque Psoriasis Achieved Completely Clear Skin And Demonstrate Favorable Safety Profile In A Once Daily Pill

While the consensus seems to underappreciate the trajectory of Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.
The Johnson &amp; Johnson Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/67f5483f584c820001291ac6/asad-haider">Analyst Asad Haider</a> upgraded the rating from Neutral to Buy, while raising the price target from $157 to $172.
The Johnson &amp; Johnson Thesis: While the Innovative Medicine business contributes around 65% of the company's revenues, it accounts for 83% of profits, which is why it is "more important for the materiality of the stock," Haider said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Although the Stelara exclusivity is around the corner, Johnson &amp; Johnson has "numerous new product cycles across multiple large markets such as IBD, psoriasis, neuropsych, multiple myeloma, bladder cancer and EGFR mutated non-small-cell lung cancer," the analyst wrote.
Moreover, pharma stocks have historically troughed about a year ahead of a major loss of exclusivity, "which could bode well for JNJ if this pattern is followed," he added.
JNJ Price Action: Shares of Johnson &amp; Johnson had declined by 2.91% to $145.63 at the time of publication on Wednesday.
Read More: <a href="https://www.benzinga.com/25/04/44698946/cell-therapy-maker-legend-biotech-an-attractive-opportunity-in-unpredictable-times-analyst">&nbsp;Cell Therapy Maker Legend Biotech Is An &#8216;Attractive Opportunity&#8217; Due To No Material Tariff Exposure: Analyst</a>
Photo: Shutterstock

Analyst Color

Long Ideas

Upgrades

Movers

This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine

Morgan Stanley analyst Terence Flynn maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and raises the price target from $163 to $164.

Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $164

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays cut Americold Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) price target from $26 to $21. Barclays analyst Anthony Powell upgraded the stock from Equal-Weight to Overweight. Americold Realty Trust shares closed at $17.50 on Tuesday. <a href="https://www.benzinga.com/quote/COLD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan slashed the price target for PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) from $210 to $160. JP Morgan analyst Alexei Gogolev downgraded the stock from Overweight to Neutral. PTC shares closed at $136.74 on Tuesday. <a href="https://www.benzinga.com/quote/PTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies lowered Xenia Hotels &amp; Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) price target from $18 to $10. Jefferies analyst David Katz downgraded the stock from Buy to Hold. Xenia Hotels shares closed at $9.22 on Tuesday. <a href="https://www.benzinga.com/quote/XHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) from $132 to $122. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Goosehead Insurance shares closed at $103.90 on Tuesday. <a href="https://www.benzinga.com/quote/GSHD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer cut the price target for Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) from $24 to $19. Oppenheimer analyst Brian Schwartz maintained an Outperform rating. Freshworks shares closed at $12.08 on Tuesday. <a href="https://www.benzinga.com/quote/FRSH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) price target from $600 to $650. Mizuho analyst Ann Hynes maintained an Outperform rating. UnitedHealth shares settled at $553.08 on Tuesday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) price target from $17 to $16. Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating. Levi Strauss shares closed at $12.42 on Tuesday. <a href="https://www.benzinga.com/quote/LEVI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $285 to $255. Mizuho analyst James Lee maintained an Outperform rating. Amazon shares closed at $170.66 on Tuesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital cut the price target for RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) from $154 to $126. BMO Capital analyst John McNulty maintained an Outperform rating. RPM shares settled at $96.97 on Tuesday. <a href="https://www.benzinga.com/quote/RPM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) price target from $157 to $172. Goldman Sachs analyst Asad Haider upgraded the stock from Neutral to Buy. Johnson &amp; Johnson shares closed at $150.00 on Tuesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-1024x584.png" alt="" class="wp-image-863746" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

COLD

FRSH

GSHD

LEVI

Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Seaport Global analyst David Joyce upgraded the rating for Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) from Neutral to Buy and announced a $27 price target. Sirius XM shares closed at $19.34 on Tuesday. <a href="https://www.benzinga.com/quote/siri/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Asad Haider upgraded Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Buy and raised the price target from $157 to $172. Johnson &amp; Johnson shares closed at $150.00 on Tuesday. <a href="https://www.benzinga.com/quote/jnj/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Korinne Wolfmeyer upgraded the rating for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Neutral to Overweight but lowered the price target from $38 to $35. Bath &amp; Body Works shares closed at $25.51 on Tuesday. <a href="https://www.benzinga.com/quote/bbwi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Edison Lee upgraded Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Underperform to Hold but lowered the price target from $202.33 to $167.88. Apple shares closed at $172.42 on Tuesday. <a href="https://www.benzinga.com/quote/aapl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andy Barish upgraded the rating for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from Underperform to Hold and maintained the price target of $76. Starbucks shares closed at $79.69 on Tuesday.  <a href="https://www.benzinga.com/quote/sbux/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-1024x601.png" alt="" class="wp-image-863674" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

AAPL

BBWI

SBUX

SIRI

This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Goldman Sachs analyst Asad Haider upgrades Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Buy and raises the price target from $157 to $172.

Goldman Sachs Upgrades Johnson & Johnson to Buy, Raises Price Target to $172

With U.S. President Donald Trump&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">tariffs</a>, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertainty.
Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) has no material exposure to tariffs, the analyst stated.
The cell therapy company&#8217;s lead product, Carvykti, is a one-time treatment for relapsed or refractory&nbsp;multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41093953/johnson-johnson-legend-biotech-partnered-blood-cancer-drug-extends-overall-survival" rel="noreferrer noopener">Johnson &amp; Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients</a>
Analyst Mitchell Kapoor notes that Legend manufactures in the U.S. for 100% of the commercial Carvykti patients in the U.S. and Europe.
In the first quarter of 2025, the company initiated commercial production of Carvykti&nbsp;at a Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) production facility under the master manufacturing and supply agreement among <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44242720/legend-biotech-reports-fourth-quarter-and-full-year-2024-results-and-recent-highlights" rel="noreferrer noopener">Legend, Janssen, and Novartis</a>.
Analyst Kapoor adds that Legend does not have to import materials for CAR-T manufacturing and thus has no material exposure to tariffs or transfer pricing.
&#8220;Legend has no tariff exposure, creating an attractive opportunity to own shares in unpredictable macroeconomic times,&#8221; HC Wainwright highlights. The analyst reiterates the Buy rating, with a <a target="_blank" href="https://www.benzinga.com/quote/LEGN/analyst-ratings" rel="noreferrer noopener">price target of $75</a>.
While Legend Biotech has several drugs in development, analyst Kapoor writes the biggest factor driving its stock is how well Carvykti performs as an earlier treatment for multiple myeloma.
The analyst is confident that Carvykti will be widely adopted in earlier lines of treatment, as the data show it&#8217;s among the best available options. &#8220;Thus, we see LEGN as considerably insulated from the regulatory risks plaguing the biotech space, and we view this as a compelling time to own the stock,&#8221; says HC Wainwright analyst.
Carvykti remains very favorably positioned compared to competitors, citing robust efficacy (particularly durability) data in the fourth- and second-line treatments, leaving little room for improvement.
HC Wainwright writes that the drug is far ahead of competitors, as it is already approved for second-line Relapsed/refractory multiple myeloma (RRMM). New therapies usually start by getting approved for use in patients who have already tried other treatments. Over time, they can receive additional approvals to be used earlier in the treatment process.
Price Action: LEGN stock is up 1.86% at $30.81 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44695936/nokia-inks-5-year-deal-with-fibrus-to-strengthen-network-security-and-analytics" target="_blank" rel="noreferrer noopener">Nokia Inks 5-Year Deal with Fibrus To Strengthen Network Security And Analytics</a></li>
</ul>

LEGN

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

Wall Street&#8217;s worst sell-off since the 2020 pandemic has sent several major indices into correction or bear territory, prompting <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44697600/stocks-rebound-chipmakers-soar-on-trade-deal-hopes-bitcoin-lags-whats-driving-markets-tuesday">a flight to safety</a>. 
<a href="https://www.benzinga.com/etfs">ETFs that provide exposure </a>to consumer staples, utilities, and healthcare—sectors that have historically been considered defensive during downturns—are now in the limelight.
Some of the top choices are:
<ul>
<li>SPDR Select Sector Fund &#8211; Consumer Staples (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>): This exchange-traded fund follows businesses that make common items such as food, drinks, and household goods. Sales of these necessities would generally continue regardless of economic downturns. Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) and Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) are among its holdings.</li>
</ul>
<ul>
<li>SPDR Select Sector Fund — Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>): Utility firms offer essential services such as electricity and water, so they would be favorites among income-hungry investors amid times of greater uncertainty. The portfolio includes NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and Pg&amp;E Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>).</li>
</ul>
<ul>
<li>Vanguard Health Care ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHT#NYSE">VHT</a>): Healthcare spending generally holds up in tough times, and VHT provides exposure to a blend of drugstore chains, medical device manufacturers, and healthcare providers. Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are among the top holdings.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/25/04/44695765/crypto-etfs-sink-as-trump-tariffs-trigger-panic-this-could-reset-the-macro-narrative">Trump Tariffs Spark $800M Crypto ETF Rout: Can The Macro Narrative Shift?</a>
Dividend-oriented ETFs are also attracting attention. The iShares Core High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDV#NYSE">HDV</a>), which owns a portfolio of financially healthy U.S. firms that pay high dividend yields, protects against declining stock prices with consistent income.
Value investing is also gaining traction. The Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>), which tracks large-cap stocks that are undervalued relative to their fundamentals, is considered a less risky means of remaining invested while reducing exposure to growth stocks with volatile price swings.
The move into defensive positioning occurs as investors process the latest ratcheting up of U.S.-China trade tensions. According to the White House, the U.S. tariff rate on Chinese imports will spike to 104% at 12:01 a.m. ET on Wednesday unless China removes retaliatory tariffs against the U.S.
The risk of blanket tariffs — a 10% base tariff on all imports to the U.S. and higher rates on major trading partners such as the EU, India, Taiwan, and Vietnam — has unsettled markets. Uncertainty about a supposedly planned 90-day tariff break, which the White House <a href="https://www.benzinga.com/news/25/04/44671308/stock-market-surge-evaporates-as-headline-roulette-plagues-traders-fake-news-white-house-says-in-response-to">called &#8220;fake news</a>,&#8221; contributed to the fluctuations.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy?_gl=1&#x2A;1mnei8t&#x2A;_gcl_au&#x2A;NzQyMjgxNjUuMTczNzYwNzI4NQ..&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NDAyMzE1Ny4yNDYuMS4xNzQ0MDIzMjMyLjAuMC4w">JPMorgan now sees</a> a U.S. recession in the second half of 2025 at 60%, and Goldman Sachs has <a href="https://www.benzinga.com/25/04/44662991/goldman-sachs-raises-risk-of-recession-to-45-jefferies-calls-tariffs-a-free-hall-pass-for-tech-giants-to-reset-their-goals">increased the chances</a> of a recession in the next 12 months to 45%.
In that environment, strategists say it&#8217;s not about going after gains — it&#8217;s about limiting losses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44698247/bitwise-turns-crypto-volatility-into-yield-with-new-etf-trio">Bitwise Turns Crypto Volatility Into Yield With New ETF Trio</a></li>
</ul>
Image: Shutterstock

Asia

Broad U.S. Equity ETFs

ETFs

COST

As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension&nbsp;(OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (gMG)</a>.
Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)&nbsp;and QMG (quantifies disease severity)&nbsp;scores over 84 weeks with sustained reductions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678645/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-t" rel="noreferrer noopener">in total immunoglobulin G (IgG)</a>.
Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p&lt;0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p&lt;0.001) mean change&nbsp;for study participants who transitioned from placebo and SOC to nipocalimab and SOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651117/johnson-johnsons-tremfya-shows-efficacy-across-multiple-domains-in-late-stage-psoriatic-arthritis-study" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study</a>
In the antibody-positive population, 45%&nbsp;of patients receiving steroids at the OLE baseline were able to decrease or discontinue steroids at the time of this data cut by more than half of the baseline dose.
<ul>
<li>Among these patients, the mean dose of prednisone decreased from 23 to 10&nbsp;mg daily.</li>
</ul>
Nipocalimab had a consistent and tolerable safety profile throughout the OLE phase.
Additional findings from the Phase 3 Vivacity-MG3 study indicate that patients treated with nipocalimab plus SOC achieved statistically significant improvements in their QMG score by -4.9 versus placebo plus SOC (p&lt;0.001) over weeks 22 and 24.
Patients in the nipocalimab plus SOC treatment group were four times more likely to sustain symptom improvement at 20 weeks than the placebo plus SOC group, as measured by a three- or greater-point improvement on the QMG score.
Results show significantly more patients treated with nipocalimab (36.4%) versus placebo (10.5%, p&lt;0.001) spent greater than 75% of the study duration, demonstrating improvements in the QMG score.
A reduction of more than three points in the QMG score indicates a decrease in the severity of the patient&#8217;s symptoms due to improvements in muscle strength, allowing patients to carry out important daily activities such as swallowing and chewing.
Price Action: JNJ stock is down 0.21% at $150.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" target="_blank" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a></li>
</ul>
Image via Shutterstock

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

<ul>
<li>New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension phase</li>
<li>Up to 128 weeks and 180 patient years of follow-up in the open-label extensiona confirm a safety profile consistent with the Phase 3 Vivacity-MG3 study&nbsp;</li>
<li>45% of the patients receiving steroids at open-label extension baseline were able to decrease or discontinue their steroid use&nbsp;</li>
<li>Additionally, the nipocalimab plus standard of care (SOC) group demonstrated four times greater odds of improving and maintaining the strength and function of different muscle groups as measured by QMGb&nbsp;response versus placebo plus SOC in the 24-week double blind phase of the study&nbsp;</li>
</ul>

Johnson & Johnson Presents New Data Showing Long-Term Sustained Disease Control With Investigational Nipocalimab In Adults With gMG

Shares of the Health Care Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NASDAQ">XLV</a>) are trading lower by 8.6% to $132.86 over the past week as tariff announcements from President Donald Trump last week spooked investors and <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">dragged major sectors</a> of the market lower. 
While healthcare is often viewed as a defensive play during times of uncertainty, the <a href="https://www.benzinga.com/general/health-care">sector</a> is not immune to the broader economic implications of escalating trade tensions.
<h2 class="wp-block-heading">What Is XLV?</h2>
The Health Care Select Sector SPDR Fund is an exchange-traded fund that tracks the performance of the Health Care Select Sector Index, which includes large U.S. healthcare companies across pharmaceuticals, biotechnology, healthcare equipment and managed care. Top holdings include Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) .
Although healthcare demand tends to be less cyclical than sectors like industrials or energy, many of XLV's components are <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">exposed to global markets</a>, supply chains and regulatory dynamics—all of which can be disrupted by a trade war.
Read Also: <a href="https://www.benzinga.com/news/25/04/44670684/whats-going-on-with-financial-select-sector-spdr-fund-xlf">What&#8217;s Going On With Financial Select Sector SPDR Fund (XLF)?</a>
<h2 class="wp-block-heading">Why Are Tariffs Hitting Healthcare—and XLV?</h2>
At first glance, healthcare might seem like an unlikely victim of tariff tensions, but the industry is more globally interconnected than it appears. Here's how tariff escalation is weighing on XLV and its underlying holdings:
<ul>
<li>Global Supply Chain Disruptions: Many medical devices and pharmaceutical ingredients are manufactured or sourced overseas. Tariffs on imported materials from countries like China can increase production costs for companies like Medtronic and Abbott Laboratories, which rely on <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">international supply chains</a> to maintain margins and deliver products at scale. </li>
<li>Pricing Pressures Intensify: Healthcare companies already face intense political scrutiny over pricing. Tariffs add another <a href="https://www.benzinga.com/news/global/25/04/44668830/we-want-fairness-white-house-trade-adviser-navarro-says-trump-administration-is-focused-on-non-tariff-cheating">layer of cost inflation</a> that may be difficult to pass along to consumers or insurers. That's especially challenging for drugmakers and device manufacturers that operate under tight pricing regulations or depend on long-term contracts. </li>
<li>Global Growth Matters: Multinational pharmaceutical companies such as Pfizer and Johnson &amp; Johnson derive a significant share of their revenue from international markets. A slowdown in global economic growth due to <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">trade tensions</a> can dampen demand for branded drugs and medical products abroad, squeezing top-line growth. </li>
<li>Market Volatility Hits Sentiment: Even though healthcare is traditionally considered defensive, the sector is still susceptible to broader market moves. Investors often rotate out of equities—including healthcare—during times of heightened uncertainty. Additionally, biotech and life sciences stocks, many of which are included in XLV, tend to be more volatile and sensitive to shifts in investor risk appetite.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>

Why Health Care Select Sector SPDR Fund (XLV) Is Moving

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson &amp; Johnson company, has received European Commission (EC) marketing authorization of&nbsp;the subcutaneous (SC) formulation of RYBREVANT&#xAE; (amivantamab), in combination with&nbsp;LAZCLUZE&#xAE; (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon&nbsp;19 deletions or exon 21 L858R substitution mutations. Additionally, it is approved as a&nbsp;monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy.
Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE&#xAE; drug delivery technology.

HALO

Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of Adult Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions Or Exon 21 L858R Substitution Mutations

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility">https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility</a>

Johnson & Johnson Announces The European Commission Has Approved Its Subcutaneous Darzalex-Based Quadruplet Regimen For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility

The new trade war precipitated by President <a href="https://www.benzinga.com/25/04/44647999/trumps-tariff-war-could-take-us-tech-industry-back-a-decade-while-china-steam-rolls-ahead-analyst-says">Donald Trump‘s tariffs</a> has turned investors against companies heavily involved in the import-export market. Instead, companies with stable revenue, low valuations and little exposure to trade are rising.
Especially ones that offer nice dividends. Today, let&#8217;s look at a couple of examples.
Then, we will consider the three best dividend funds to capture this trend.
Consider companies like Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) (6.07% dividend right now), which does not purchase or sell products in overseas markets, or tobacco giant Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) (7.25% dividend), which sells most of its products in the USA.
Past that, dividend stocks and funds have been performing well in 2025.
&#8220;Dividend-oriented strategies have performed well in the first quarter of 2025,&#8221; said William Connor, CFA, CFP, partner at Sax Wealth Advisors. &#8220;The SPDR S&amp;P Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDY#NYSE">SDY</a>) generated a positive return during Q1 2025 of 2.71%, which compares favorably with the S&amp;P 500, which lost 4.55% in the first quarter of 2025.&#8221;
Although the S&amp;P 500 has outperformed over the last year, increasing 7.1% while the SDY was up 3.86%, dividend stocks tend to be less volatile, often due to the more defensive nature of the economic sectors in which they operate. &#8220;Ned Davis Research conducted a study of dividend-paying companies compared to non-dividend-paying companies,&#8221; Connor noted. &#8220;The results illustrated what many investors intuitively feel; dividend stocks exhibit lower volatility than non-dividend payers and a broad index like the S&amp;P 500.&#8221;
That data matters at a time when the Trump administration has sought a level playing field on tariffs, causing major upheaval in global markets.
&#8220;The impact of potential tariffs on the economy is unknowable at this point, given that the specifics have yet to be announced,&#8221; Connor said. &#8220;What is likely is the uncertainty around tariffs (amounts, sectors, and exemptions, for example) is leading many investors to be concerned about the outlook for US stocks.&#8221;
Since dividend stocks have been less volatile over time than the average stock, it&#8217;s reasonable for investors concerned with the growth outlook to focus on them. &#8220;The dividend payment provides a steady, predictable return to help manage volatility and risk,&#8221; Connor added.
Given the volatility linked to trade and tariffs, will that be the case going forward? Yes and no.
&#8220;In the short-term, tariffs are likely to be seen as a negative for dividend stocks – particularly globally-focused companies – as tariffs increase the price of imported goods or raw materials, which can impact profitability,&#8221; said Rob Edwards, managing director and senior portfolio manager at Florida-based Edwards Asset Management.
In the long run, however, Edwards believes dividend stocks should prosper, even with tariffs, as they are typically more mature companies that have proven resilient to many economic challenges.
&#8220;I believe that you should own dividend stocks to invest throughout an entire market cycle, not around it,&#8221; he noted.
<h2 class="wp-block-heading">Three Solid Dividend ETFs</h2>
Rather than take your chances with one or two individual dividend-paying stocks, curb some downside risk by leveraging dividend exchange-traded funds, where you can also get some bang for your buck.
<h3 class="wp-block-heading">SPDR S&amp;P Dividend ETF</h3>
Like the best dividend ETFs, the SPDR S&amp;P Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDY#NYSE">SDY</a>) is a tax-efficient, low-cost, highly liquid investment with broad exposure to high-quality stocks.
The fund aims to produce investment results corresponding to the total return performance of the S&amp;P High Yield Dividend Aristocrats Index. &#8220;The fund really focuses on S&amp;P Composite 1500 Index companies that have followed a managed-dividends policy of consistently increasing dividends every year for at least 20 consecutive years,&#8221; Connor said.
Dividend payments are about 0.80% and the fund has returned 4.76% year-to-date.
Dividend ETFs are not flashy, but they&#8217;re steady, and that&#8217;s what Steven Kibbel, a financial planner and chief editorial advisor at Gold IRA Companies in Franklin, Tenn. &#8220;Many people, especially retirees I work with, like them because they give regular income without needing to sell shares. That matters when you&#8217;re trying to make your savings last. These funds mostly hold big companies that keep paying dividends no matter what&#8217;s going on in the market. Think utilities, healthcare, and food companies. That kind of thing.&#8221;
<h3 class="wp-block-heading">Schwab U.S. Dividend Equity ETF</h3>
One dividend fund Kibbel favors holds those same traits &#8211; Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>).
&#8220;It&#8217;s simple, low-cost, and holds strong companies with solid financials,&#8221; he said. &#8220;I&#8217;ve used it for years with clients who want income and stability. Another one I use is iShares Select Dividend (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>). That one focuses more on higher yields. It&#8217;s not always the right fit for everyone, but it works well if income is the top goal.&#8221;
SCHD currently offers a healthy 3.85% dividend; its year-to-date returns are 2.93% compared to 4.49% for its category.
<h3 class="wp-block-heading"> iShares Core High Dividend ETF</h3>
iShares Core High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDV#NYSE">HDV</a>) is another popular pick among money managers.
The fund holds 75 high-dividend-paying stocks and is energy-heavy, with Exxon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) comprising two of the top three fund holdings. Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also joins the group. 
Big-cap brand names are the fund&#8217;s bread and butter, although no one stock tops 9.3% of its holdings (that would be Exxon). The fund is up 7.75% and has generally landed in the 10% annual return range since it launched in 2011. HDV also offers a robust 3.41% dividend yield with an ultra-low 0.8% expense ratio.
<h2 class="wp-block-heading">What To Look For With Dividend ETFs</h2>
Before you get rolling on dividend funds and kick some tires, have a game plan to leverage that matches you up with the right fund.
&#8220;You want an ETF that holds reliable stocks with a history of raising dividends annually, and that offers a true hedge against inflation,&#8221; said Ketti Rose, the CEO and founder of Wealthy Femme, a money management platform geared toward women investors. &#8220;Also, ensure the expense ratio is low – the less, the better, as there&#8217;s no need to sacrifice returns for fees.&#8221;
Additionally, seek out ETFs that maintained steady — or even increased — dividends through past recessions (e.g., in 2008 or 2020). &#8220;That&#8217;s a strength you can depend on,&#8221; Rose noted.
<h2 class="wp-block-heading">Predictable Trading In Unpredictable Times</h2>
In a market dominated by tariff tensions, geopolitical surprises and Fed uncertainty, Matt Maley's technical approach delivers clear entry/exit points for consistent income potential. Try it <a href="https://www.benzinga.com/premium/ideas/7-day-free-trial-matt-maley-inner-circle/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0407&amp;utm_campaign=7daytrial">free for 7 days</a>. Gain Trading Confidence &amp; Income Potential. 
Photo: Shutterstock

Opinion

iShares Dow Jones Select Dividend Index Fund

SCHD

Sit Out Market Drama With These 3 Dividend Funds

Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Friday announced topline results from Phase&nbsp;3b&nbsp;APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">response to standard therapies</a>.
The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44644676/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-an" rel="noreferrer noopener">compared to placebo</a>.
In the Phase&nbsp;3b&nbsp;APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims" rel="noreferrer noopener">US Judge Rejects Another Johnson &amp; Johnson Attempt To Use Bankruptcy For Talc Cancer Claims</a>
Data were consistent with the well-established safety profile of Tremfya&nbsp;with no new safety signals identified.
APEX is a Phase&nbsp;3b&nbsp;study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya&nbsp;on inhibition of structural damage in patients with active PsA.
Results from the APEX study are being prepared for presentation at upcoming medical congresses.
<h2 class="wp-block-heading">Johnson &amp; Johnson Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson &amp; Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson &amp; Johnson, the 200-day moving average sits at $156.5, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $155.82. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/04/44647720/matador-resources-sells-eagle-ford-assets-announces-potential-buybacks" target="_blank" rel="noreferrer noopener">Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks</a></li>
</ul>
Photo by Tada Images via Shutterstock

Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

Press Releases

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

B of A Securities

Morgan Stanley

Goldman Sachs

RBC Capital

Barclays

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL